Investors continue to drive Virpax Pharmaceuticals (NASDAQ:VRPX) stock higher on Wednesday after Tuesday’s major company news emerged.
The Pennsylvania-based firm said yesterday that it received a written response from the U.S. Food and Drug Administration (FDA) concerning its . According to InvestorPlace writer William White, the “response from the FDA is for the company’s pre-investigational new drug and opens the way for Virpax Pharma to submit a New Drug Application (NDA) for MMS019.”
In turn, the NDA could be used as a daily treatment against the “inhibition of viral replication of SARS-CoV-2 and influenza in animals.” And according to the release, Virpax Pharma is considering submitting its NDA to the Office of Non-Prescription Drugs.
With all of this in mind, what are investors saying about VRPX stock? Let’s take a closer look to find out.
WEDNESDAY PLANS 36 is my new base. 38.50 break 👀 Swing winner. BANG!! 11 break 👀 would send it hold 16, break 20! 10.25 buy order ready 22 entry and SL. 24 break is key! bullish above 3 hold 8, break 8.50 & 🚀 14 break 👀
— Donnie Stocks (@DonnieStocks)
https://twitter.com/redhoodtrading/status/1427724216133169154
Watch for a flush too
— Zack Morris (@MrZackMorris)
https://twitter.com/Ultra_Calls/status/1427993579511848960
https://www.reddit.com/r/RDTS/comments/p6b7l8/vrpx_compliments_of_uwilsash42_a_260_green_day/?utm_source=share&utm_medium=web2x&context=3
If you’re looking for more updates from Wall Street,
InvestorPlace has all the latest stock market news you need to know. This includes the latest on PharmaCyte Biotech (NASDAQ:PMCB), Dogecoin (CCC:DOGE-USD) and Palantir (NYSE:PLTR) on Wednesday. You can find all of this info at the links below!
More Wednesday Stock ÃÛÌÒ´«Ã½ News
- PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket
- What Is the Dogecoin Manifesto? 4 Things to Know as DOGE Prices Drop
- Dear Dogecoin Crypto Fans, Vitalik Buterin Just Stepped Up to Save the Day
- PLTR Stock: The $11.4M Catalyst Sending Palantir Gaining Today
On the date of publication, Nick Clarkson did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Nick Clarkson is a web editor at InvestorPlace.
